The VICTORION-INIATATE study demonstrated that initiating inclisiran, a highly potent lipid-lowering therapy, upon failure to achieve lipid targets with statins, yielded superior outcomes compared to standard care. This approach facilitated a greater proportion of patients in reaching LDL-C targets recommended by current guidelines. Presently, the conventional management of cholesterol disorders in the US routinely falls short of attaining treatment goals for the majority of patients.

In this interview, Michael J. Koren, MD, FACC, and C. Noel Bairey Merz, MD, FACC discuss results from the VICTORION-INITIATE randomized trial.

Related References:

1. Koren, M, Rodriguez, F, East, C. et al. An Inclisiran First Strategy vs Usual Care in Patients with Atherosclerosis. J Am Coll Cardiol. null2024, 0 (0) .https://doi.org/10.1016/j.jacc.2024.03.382
2. Kosmas, C. E., Muñoz Estrella, A., Skavdis, A., Peña Genao, E., Martinez, I., & Guzman, E. (2020). Inclisiran for the Treatment of Cardiovascular Disease: A Short Review on the Emerging Data and Therapeutic Potential. Therapeutics and clinical risk management, 16, 1031–1037. https://doi.org/10.2147/TCRM.S230592

Clinical Topics: Dyslipidemia, Lipid Metabolism, Nonstatins, Acute Coronary Syndromes, Prevention

Keywords: ACCELLite, ACC24, Inclisiran, Cholesterol